Is Otonomy Inc (NASDAQ:OTIC) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and financial guidance. Consistent with previously stated timing, the company expects to have results for the Phase 3 trial of OTIVIDEX in Ménière’s disease in the third quarter of 2020, the Phase 1/2 trial of OTO-313 in tinnitus patients in the second quarter of 2020, and the Phase 1/2 trial of OTO-413 in patients with hearing loss in the second half of 2020. The company finished 2019 with approximately $61 million in cash, cash equivalents and short term investments and expects that its current capital is sufficient to fund operations through the three clinical trials and into 2021.
SAN DIEGO, Feb. 24, 2020 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
SAN DIEGO, May 07, 2020 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported.
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 43rd Annual MidWinter Meeting, to be held January 25-29, in San Jose, California. “Our multiple presentations at ARO again this year highlight our broad pipeline in neurotology, with data to be presented in support of our programs addressing the treatment of both inherited and acquired forms of hearing loss as well as protection against cisplatin ototoxicity," said David A. Weber, Ph.D., president and chief executive officer of Otonomy.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
David Weber has been the CEO of Otonomy, Inc. (NASDAQ:OTIC) since 2010. This analysis aims first to contrast CEO...
Q4 2019 Otonomy Inc Earnings Call
SAN DIEGO, Feb. 20, 2020 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided a business update related to the COVID-19 pandemic. “Our first priority during this international crisis has been to ensure the health and safety of our employees, patients enrolled in our clinical trials, and healthcare professionals at our study sites in the United States and Europe,” said David A. Weber, Ph.D., president and CEO of Otonomy.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and.
Otonomy, Inc. (NASDAQ:OTIC) shareholders should be happy to see the share price up 27% in the last quarter. But that...
Otonomy (OTIC) delivered earnings and revenue surprises of 23.40% and -15.46%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation (AGTC) focused initially on treating GJB2 deficiency for congenital hearing loss, and preclinical results demonstrating the therapeutic potential of a class of compounds being evaluated for otoprotection against cisplatin-induced hearing loss (CIHL).
Investors need to pay close attention to Otonomy (OTIC) stock based on the movements in the options market lately.
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced preclinical results from the company’s gene therapy collaboration with Applied Genetic Technologies Corporation (AGTC) that support the selection of a product candidate for development as a treatment for gap junction beta-2 (GJB2) deficiency, the most common cause of congenital hearing loss. “Working with AGTC, we have identified novel and proprietary capsids that are capable of transducing support cells of the cochlea, which are the relevant target cells for treating GJB2 deficiency," said David A. Weber, Ph.D., president and chief executive officer of Otonomy.
As of late, it has definitely been a great time to be an investor in Otonomy.
Top Ranked Momentum Stocks to Buy for December 3rd
SAN DIEGO, Nov. 26, 2019 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.